"Tumor Immunology Meets Oncology IV", 23rd and 24th May 2008 Martin Luther University Halle-Wittenberg, Halle, Germany

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2008 Aug 30

PMID 18751976

Citations 1

Authors

Juergen Bukur

Dennis Loeffler

Chiara Massa

Lutz Mueller

Dagmar Riemann

Hans-Joachim Schmoll

Barbara Seliger

Affiliations

Soon will be listed here.

Citing Articles

A phase II trial of sorafenib in metastatic melanoma with tissue correlates.

Ott P, Hamilton A, Min C, Safarzadeh-Amiri S, Goldberg L, Yoon J PLoS One. 2011; 5(12):e15588.

PMID: 21206909 PMC: 3012061. DOI: 10.1371/journal.pone.0015588.

References

Hanson M, Ozenci V, Carlsten M, Glimelius B, Frodin J, Masucci G . A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients. Cancer Immunol Immunother. 2006; 56(7):973-84. PMC: 11030861. DOI: 10.1007/s00262-006-0261-4. View

Luo W, Ko E, Hsu J, Wang X, Ferrone S . Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol. 2006; 176(10):6046-54. DOI: 10.4049/jimmunol.176.10.6046. View

Dong X, An B, Salvucci Kierstead L, Storkus W, Amoscato A, Salter R . Modification of the amino terminus of a class II epitope confers resistance to degradation by CD13 on dendritic cells and enhances presentation to T cells. J Immunol. 1999; 164(1):129-35. DOI: 10.4049/jimmunol.164.1.129. View

Peipp M, Lammerts van Bueren J, Schneider-Merck T, Bleeker W, Dechant M, Beyer T . Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood. 2008; 112(6):2390-9. DOI: 10.1182/blood-2008-03-144600. View

Takahashi A, Hanson M, Norell H, Havelka A, Kono K, Malmberg K . Preferential cell death of CD8+ effector memory (CCR7-CD45RA-) T cells by hydrogen peroxide-induced oxidative stress. J Immunol. 2005; 174(10):6080-7. DOI: 10.4049/jimmunol.174.10.6080. View

Wang Z, Zhang L, Qiao A, Watson K, Zhang J, Fan G . Activation of CXCR4 triggers ubiquitination and down-regulation of major histocompatibility complex class I (MHC-I) on epithelioid carcinoma HeLa cells. J Biol Chem. 2007; 283(7):3951-9. DOI: 10.1074/jbc.M706848200. View

Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot M, Ruiz-Cabello F, Garrido F . MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol. 2007; 256:139-89. DOI: 10.1016/S0074-7696(07)56005-5. View

Ratajczak M, Zuba-Surma E, Wysoczynski M, Ratajczak J, Kucia M . Very small embryonic-like stem cells: characterization, developmental origin, and biological significance. Exp Hematol. 2008; 36(6):742-51. PMC: 2430762. DOI: 10.1016/j.exphem.2008.03.010. View

Mueller L, Luetzkendorf J, Mueller T, Reichelt K, Simon H, Schmoll H . Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction. Stem Cells. 2006; 24(12):2753-65. DOI: 10.1634/stemcells.2006-0108. View

10.

Aboody K, Najbauer J, Danks M . Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 2008; 15(10):739-52. DOI: 10.1038/gt.2008.41. View

11.

Wang E, Worschech A, Marincola F . The immunologic constant of rejection. Trends Immunol. 2008; 29(6):256-62. DOI: 10.1016/j.it.2008.03.002. View

12.

Mueller T, Mueller L, Luetzkendorf J, Voigt W, Simon H, Schmoll H . Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. Tumour Biol. 2006; 27(2):71-83. DOI: 10.1159/000092324. View

13.

Ratajczak M, Zuba-Surma E, Machalinski B, Ratajczak J, Kucia M . Very small embryonic-like (VSEL) stem cells: purification from adult organs, characterization, and biological significance. Stem Cell Rev. 2008; 4(2):89-99. DOI: 10.1007/s12015-008-9018-0. View

14.

Gamzatova Z, Villabona L, van der Zanden H, Haasnoot G, Andersson E, Kiessling R . Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer. Tissue Antigens. 2007; 70(3):205-13. DOI: 10.1111/j.1399-0039.2007.00875.x. View

15.

Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Antognoli A . Antimetastatic activity of a preventive cancer vaccine. Cancer Res. 2007; 67(22):11037-44. DOI: 10.1158/0008-5472.CAN-07-2499. View

16.

Boman B, Wicha M . Cancer stem cells: a step toward the cure. J Clin Oncol. 2008; 26(17):2795-9. DOI: 10.1200/JCO.2008.17.7436. View

17.

Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J . Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005; 65(8):3307-18. DOI: 10.1158/0008-5472.CAN-04-1874. View

18.

Studeny M, Marini F, Champlin R, Zompetta C, Fidler I, Andreeff M . Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002; 62(13):3603-8. View

19.

Wang X, Ko E, Peng L, Gillies S, Ferrone S . Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2. Cancer Res. 2005; 65(15):6976-83. DOI: 10.1158/0008-5472.CAN-04-2328. View

20.

Sackstein R, Merzaban J, Cain D, Dagia N, Spencer J, Lin C . Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone. Nat Med. 2008; 14(2):181-7. DOI: 10.1038/nm1703. View